Glipy Met 500 SR Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby reducing fasting and postprandial blood glucose levels. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which promote insulin secretion and suppress glucagon release in a glucose-dependent manner, contributing to improved glycemic regulation without significant risk of hypoglycemia. The sustained-release formulation ensures a gradual release of Metformin, improving gastrointestinal tolerability and patient compliance. Glipy Met 500 SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly when monotherapy with either agent is insufficient. It is essential to monitor renal function prior to and during therapy, as Metformin is contraindicated in patients with severe renal impairment. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish with continued use. This combination therapy offers a complementary mechanism of action, providing effective blood glucose management with a favorable safety profile.